Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 12/20 | 0.66 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.52 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.52 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15395991 | 0.92 | IL2 (0.56) | IL2STIM1ORAI1ORAI2RAB9A | |
| SCHEMBL5550953 | 0.89 | IL2 (0.66) | IL2STIM1ORAI1ORAI2POLB | |
| SCHEMBL15395771 | 0.87 | IL2 (0.65) | IL2STIM1ORAI1ORAI2RAB9A | |
| SCHEMBL15214056 | 0.85 | IL2 (0.54) | IL2STIM1ORAI1ORAI2POLB | |
| SCHEMBL15395892 | 0.85 | STIM1 (0.63) | IL2STIM1ORAI1ORAI2POLB | |
| SCHEMBL15395773 | 0.84 | STIM1 (0.57) | IL2STIM1ORAI1ORAI2RAB9A | |
| SCHEMBL15395893 | 0.84 | IL2 (0.65) | IL2STIM1ORAI1ORAI2RAB9A | |
| SCHEMBL15395777 | 0.83 | STIM1 (0.63) | IL2STIM1ORAI1ORAI2POLB | |
| SCHEMBL1701939 | 0.82 | IL2 (0.58) | IL2STIM1ORAI1ORAI2POLB | |
| SCHEMBL15395954 | 0.82 | ORAI1 (0.54) | IL2STIM1ORAI1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493427-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-9090570-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-20130309272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2006081391-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 21/4885STIM1 2094/4885ORAI1 1129/4885 |
| US-20130309272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 22/4885STIM1 2122/4885ORAI1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.